ADAGENE INC-ADR (ADAG)

Company Profile

Adagene, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of novel antibody-based cancer immunotherapies. The company is headquartered in Suzhou, Jiangsu and currently employs 248 full-time employees. The company went IPO on 2021-02-09. The firm is principally engaged in the research, development and production of monoclonal antibody drugs for cancers. The Company’s main products include: ADG106 is being developed for the treatment of advanced solid tumors and non-Hodgkin's lymphoma, or NHL. ADG126 is designed to address the toxicity and efficacy issues related to the MOA of existing approved CTLA-4 immuno-oncology therapies and to expand the potential of CTLA-4 as a target for the treatment of cancer. ADG116 is designed to target a unique conserved epitope of CTLA-4. And ADG104, a monospecific antibody that targets PD-L1 and is in Phase Ib and Phase II clinical trials concurrently in China.

Company Info

ADAGENE INC-ADR

4F, Building C14, No. 218, Xinghu Street, Suzhou Industrial Park

Suzhou JIANGSU 215123

P: 8651287773632.0

CEO: Peter (Peizhi) Luo

Employees: 248

Website: https://www.adagene.com/